JDTic is a powerful antagonist of kappa-opioid receptors (KOR), effectively inhibiting the antinociceptive effects induced by the κ-agonist U50, 488.

JDTic (10 mg/kg, i.p.) decreases alcohol self-administration, suppresses cue-induced reinstatement of alcohol seeking, and specifically blocks the effects of a KOR agonist at the 2 h pretreatment time point. JDTic (30 mg/kg, i.g.) significantly blockes U50,488-induced diuresis immediately in rats. JDTic (2.5-16 mg/kg, s.c.) dose-dependently blocks the antinociceptive response of nicotine in the tail-flick test but has no effect in the hot-plate assay or body temperature assessments at any dose tested in the mice injected with nicotine. JDTic (3 mg/kg, i.p.) is capable of reversing anxiety-like behavior in the rat model of hangover anxiety.